Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd has demonstrated significant advancement in its diagnostic capabilities, highlighted by the successful launch of its CE-Marked Nu.Q NETs automated assay and its strategic expansion across a multitude of international hospitals, indicating a broadening commercial presence. The company is strategically enhancing its human diagnostics licensing by partnering with industry leaders such as Werfen and Hologic, which is expected to bolster its market penetration and drive future revenue growth. Furthermore, the potential rollout of the Nu.Q Vet Feline Test stands to double the addressable market in companion animal diagnostics, complementing the established success of the Nu.Q Vet Cancer Test, thereby positioning VolitionRX for sustained financial momentum.

Bears say

VolitionRX Ltd faces increased dilution risk, which has prompted a reduction in its price target from $5.00 to $3.00, reflecting concerns over the company’s financial stability and potential shareholder value erosion. This dilution risk may stem from the need for additional capital to support its ongoing research and development efforts in the competitive field of epigenetics and diagnostics. Consequently, these financial challenges contribute to a fundamentally negative outlook on the company’s stock performance.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.